N
Nafsika Afentou
Researcher at University of Birmingham
Publications - 9
Citations - 57
Nafsika Afentou is an academic researcher from University of Birmingham. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 2, co-authored 5 publications receiving 24 citations. Previous affiliations of Nafsika Afentou include Lund University.
Papers
More filters
Journal ArticleDOI
A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation
Nafsika Afentou,Philip Kinghorn +1 more
TL;DR: The ICECAP-A is correlated with health-related quality of life but is most appropriately regarded as a complement for and not a substitute to the EuroQol 5-dimension 3-level and EuroQOL 5- dimension 5-level in particular.
Journal ArticleDOI
Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review
TL;DR: The aim of this study is to appraise recent economic evaluation studies on PD management in order to update the existing knowledge and facilitate decision making onPD management by assessing the cost‐effectiveness of all types of PD interventions.
Journal ArticleDOI
Eliciting a monetary threshold for a year of sufficient capability to inform resource allocation decisions in public health and social care.
Philip Kinghorn,Nafsika Afentou +1 more
TL;DR: In this paper, the authors used a deliberative approach to elicit a monetary threshold for an additional YSC/YFC, with a range of £33,500 to £36,150 emerging as the value of a YSC and YFC.
Journal ArticleDOI
Proxy responses to ICECAP-A: Exploring variation across multiple proxy assessments of capability well-being for the same individuals.
Philip Kinghorn,Nafsika Afentou +1 more
TL;DR: The factual versus empathetic approaches identified from qualitative analysis in this study match to the concept of a proxy-proxy versus proxy-patient perspective, previously outlined in the literature.
Journal ArticleDOI
Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT
Detlef Bockenhauer,Karl McKeever,Nafsika Afentou,Moin A. Saleem,Christopher D. O’Sullivan,Joanna D. Davies,Jana B. Nieder,D. P. Domonov,Bartolomé Estrada Turra,Matthew Rampley,Холиков Музаффар Абдигаппарович,AMNH Mammalogy,Beverly A. DeVries,Federica Mennuni,Nadejda Gadjeva,Gang Chen,Buzas, Jeffrey,Izkk- MkW- vkfnR; fd'kksj lkjos,R.Yu. Shamgulov,Parlo Singh,Mamatov I.A. +20 more
TL;DR: In this paper , the authors showed that giving daily low-dose prednisone/prednisolone for 5-7 days during an upper respiratory tract infection reduces the risk of relapse.